Introduction Ischaemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide and poses an ...
As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...
MedPage Today on MSN
Stroke Trial Tips Scale Further to Favor Intra-Arterial Lytic After EVT
CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...
Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...
Rochester, MN - Starting a 72-hour infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) after successful MI reperfusion therapy apparently suppressed aldosterone levels and may have had a ...
Ischemic heart disease is the leading cause of death globally, causing approximately 9 million deaths annually. Currently, reperfusion therapy (such as thrombolysis or interventional procedures) is ...
Mesenchymal stromal cells (MSCs) were cultured on microcarriers in 3D rotating bioreactors and primed with ginsenoside Rg1 to enhance cell proliferation. Artificial cell-derived vesicles (ACDVs) from ...
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...
Alternative model systems to study ischemia-reperfusion are needed to support a wide range of disease-related investigations in the life sciences. Ischemia and reperfusion are relevant to many disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results